Provided by Tiger Fintech (Singapore) Pte. Ltd.

BEIGENE

156.100
+1.2000.77%
Volume:4.67M
Turnover:721.11M
Market Cap:240.24B
PE:-42.24
High:156.500
Open:156.400
Low:151.400
Close:154.900
Loading ...

Company Profile

Company Name:
BEIGENE
Exchange:
SEHK
Establishment Date:
2010
Employees:
11000
Office Location:
Aeschengraben 27,21st Floor,Basel,Basel-Stadt,Switzerland
Zip Code:
4051
Fax:
- -
Introduction:
BeiGene, Ltd. is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. The Company has an oncology pipeline of more than 50 investigational assets. Its products include BRUKINSA, TEVIMBRA, XGEVA, BLINCYTO, KYPROLIS, POBEVCY, and others. BRUKINSA is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). TEVIMBRA is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is engaged in the sale of XGEVA, BLINCYTO and KYPROLIS in China under a license from Amgen and POBEVCY in China under a license from Bio-Thera. The Company’s pipeline products include Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, Xaluritamig, and others.

Directors

Name
Position
John V. Oyler
Co-Founder, Chairman and Chief Executive Officer
Ranjeev Krishana
Lead Director
Alessandro Riva
Director
Anthony C. Hooper
Director
Corazon D. Sanders
Director
Margaret Dugan
Director
Michael Goller
Director
Olivier Brandicourt
Director
Qingqing Yi
Director
Shalini Sharp
Director
Xiaodong Wang
Director

Shareholders

Name
Position
John V. Oyler
Co-Founder, Chairman and Chief Executive Officer
Xiaobin Wu
President, Chief Operating Officer and General Manager, China
Aaron Rosenberg
Chief Financial Officer
Chan Lee
Senior Vice President, General Counsel
Lai Wang
Global Head of R&D